Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2025-02-06 00:00:00 ET · period of report 2025-02-04 · accession 0000950170-25-015682 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-06 | 2025-02-04 | WVE | Moran Kyle | CFO | A - Grant | $0.00 | +42.0K | 89.2K | +89% | $0 |
| D | 2025-02-06 | 2025-02-04 | WVE | Moran Kyle | CFO | A - Grant | $0.00 | +252.0K | 252.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-02-04 | A | A | 42,000 | $0.00 | 89,218 | D | — | — | (F1) Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2026 through February 8, 2029. (F2) Includes 2,441 ordinary shares acquired on January 14, 2025, under the issuer's 2019 Employee Share Purchase Plan. |
| 2 | Derivative | Share Option (right to buy) | 2025-02-04 | A | A | 252,000 | $0.00 | 252,000 | D | $11.74 · — to 2035-02-04 | 252,000 Ordinary Shares | (F3) The option vests as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029. |